ABSTRACT: Background. No objective data are available to assess the potential damage induction chemotherapy alone contributes to swallowing physiology and salivary production in patients with locally and regionally confined head and neck cancer. Methods. Thirteen patients with head and neck cancer were evaluated preinduction and postinduction chemotherapy. Assessment included: (1) percentage of nutrition taken orally and food consistencies in diet; (2) videofluorographic swallow evaluation; (3) whole mouth saliva collection; (4) quality-of-life questionnaire; and (5) pain and oral mucositis scores. Results. All patients were able to consume most foods and took 100% of their nutrition orally both preinduction and postinduction chemotherapy.
INTRODUCTION
Over the past 30 years, there has been increasing interest in the effects of treatment for head and neck cancer on oropharyngeal swallow. Initial attention was placed on surgical procedures and their impact on swallow function. [1] [2] [3] [4] [5] [6] Attention then turned to radiation therapy and its effects on oropharyngeal swallow. Currently, chemotherapy in combination with radiotherapy, either sequentially or concurrently, is being studied. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Swallowing dysfunction and altered saliva production are common sequelae of radiation with or without chemotherapy in the management of head and neck cancers. The quantitative and qualitative alteration in swallowing physiology and saliva production caused by radiation alone [17] [18] [19] [20] [21] [22] [23] [24] [25] or radiation with chemotherapy [26] [27] [28] [29] [30] [31] are well documented. The damage to swallowing structures caused by radiation with chemotherapy is much greater than that seen with radiation alone. 32 Clinically, chemotherapy alone does not seem to alter swallow biomechanics. However, no objective data are available to assess the magnitude of damage chemotherapy alone may contribute in combined modality therapy. In order to understand the complex effects of treatment for head and neck cancer on oropharyngeal swallow and those factors that create the greatest changes, all aspects of treatment must be examined. This present study serves as a pilot examination of the effects of chemotherapy alone in a small number of patients to determine whether a larger study of induction chemotherapy effects on oropharyngeal swallow is warranted.
The primary purpose of this pilot study was to document the effect of induction chemotherapy alone on swallowing physiology for the treatment of head and neck cancers. In addition to providing mucosal protection and hydration to the oral cavity, the oropharyngeal axis, and the esophagus, saliva also plays an important role in the oral preparatory phase of swallowing mechanics. 33 Therefore, we evaluated swallowing measures and saliva production in patients preinduction and postinduction chemotherapy to assess the effect of chemotherapy on these separate endpoints. We also evaluated pain and mucositis that might affect swallowing in these patients.
MATERIALS AND METHODS

Patients
In this prospective study, 13 patients with local and regional stage IV head and neck cancer whose treatment plan included induction chemotherapy were consecutively enrolled in the study. The patients, 12 men and 1 woman, were between the ages of 31 and 68 (mean age, 53 years). The induction chemotherapy protocol consisted of docetaxel (75 mgm/M 2 on day 1), cisplatin (75 mgm/M 2 on day 1), and 5 fluorouracil (750 mgm/M 2 /day on days 1-5). After completion of 2 to 3 cycles of induction chemotherapy administered 3 weeks apart, all patients underwent concomitant chemoradiotherapy. The average time between completion of induction chemotherapy and concomitant chemoradiotherapy was 15 days.
Study protocol
The study protocol was approved by the Institutional Review Board of Northwestern University. Each patient received an assessment preinduction and postinduction chemotherapy which included: (1) documentation of percent nutrition taken orally and the food consistencies in the patient's diet; (2) videofluorographic swallow evaluation; (3) whole-mouth saliva collection; (4) quality-of-life questionnaire; and (5) pain and oral mucositis scores.
Dietary consistencies and oral intake.
Preinduction and postinduction chemotherapy, patients were asked which of the various food consistencies they included in their oral diets (thin liquids, thick liquids, paste/pureed foods, soft-masticated foods, or crunchy foods). An oral diet was considered normal if the patient could consume all of these consistencies. Patients were also asked to estimate the percentage of their nutrition they consumed orally.
Videofluorographic swallow evaluation. During both the preinduction and postinduction videofluorographic studies, patients were asked to take 3 swallows each of 3 mL and 10 mL of thin liquid, 3 swallows of 3 mL of pudding barium, and 3 swallows of one-fourth piece of a shortbread cookie. During the study, the fluoroscopy tube was focused on the lips anteriorly, the cervical vertebrae posteriorly, the soft palate superiorly, and the bifurcation of the airway inferiorly. Fluoroscopic data were recorded on video at 30 frames per second.
Whole-mouth saliva collection.
Whole-mouth saliva was collected using the Saxon Test. 34 During this test, stimulated whole-mouth saliva production was evaluated by weighing a 4" 3 4" sterile gauze pad before and after the patient chewed the gauze for 2 minutes.
Patient-reported quality of life, patient-reported pain, and mucositis scoring. Patients were asked to complete the Performance Status Scale for Head and Neck Cancer Diet and Eating in Public subscales 35 at both evaluation points. Each scale is scored from 0 to 100, with 100 representing the best function. For analysis, the scale results were dichotomized as 100 versus <100. Patients reported pain at each evaluation point on a 10-point scale, with 0 representing no pain and 10 representing extreme pain. 36 Mucositis was measured using a validated scale for assessing ulceration and erythema at various sites in the mouth. 37 For analysis, this scale was dichotomized as no mucositis versus some mucositis. The mucositis scale on the Common Toxicity Criteria version 3.0 was not scored during the provision of induction chemotherapy.
Data reduction from videofluorographic swallow study
The following measures and observations were made from the videofluorographic studies: (1) oral transit time: time in seconds it takes the bolus to move through the oral cavity; (2) pharyngeal transit time: time in seconds for the bolus to move through the pharynx; (3) pharyngeal delay time: time in seconds required to trigger the pharyngeal swallow; (4) pharyngeal response time: time in seconds required for the pharyngeal swallow to activate; (5) duration of laryngeal vestibule closure: time in seconds that the laryngeal entrance between the arytenoid and the base of the epiglottis is closed during swallow; (6) duration of cricopharyngeal opening: time in seconds that the cricopharyngeal region is open during swallow; (7) approximate percent oral residue: estimated percent of bolus residue in the oral cavity after the swallow; (8) approximate percent pharyngeal residue: estimated percent of bolus residue in the pharynx after the swallow; and (9) oropharyngeal swallowing efficiency (OPSE): percent of the bolus swallowed divided by the total transit time. OPSE is a global measure that describes the interaction of speed of movement of the bolus and the safety and efficiency of the mechanism in clearing material from the oropharynx while preventing aspiration. 38 
Statistical analysis
Change in dichotomous measures of eating ability were assessed for statistical significance using the McNemar test. 39 The Wilcoxon signed rank test 39 was used to assess change in saliva weight, pain, and mucositis score. Mixed linear model analysis using maximum likelihood tests was used to compare change in the temporal measures, as measured by videofluoroscopy, pooling data across all bolus types. The effect of each demographic and disease variable on OPSE was evaluated by including them one at a time into the mixed effects model as a covariate.
RESULTS
Patient demographics and tumor characteristics are detailed in Table 1 . Mean cumulative dose of induction chemotherapy consisted of docetaxel (289 mgm), cisplatinum (307 mgm), and 5 fluorouracil (15,730 mgm). Eleven patients received 2 cycles of induction chemotherapy, whereas 2 patients had 3 cycles of induction chemotherapy. Data collection was completed before any additional tumor treatment was initiated, including radiation therapy and any concurrent chemotherapy.
The effect of the variables of age, race, primary tumor site (oropharynx vs other sites combined), T classification, smoking history (smokes currently vs not smoking currently), and alcohol history (drinks currently vs not drinking) on OPSE were examined. Sex, N classification, M classification, and disease stage were not evaluated because the sample sizes were too small. Age (p 5 .88), primary tumor site (p 5 .94), T classification (p 5 .27), smoking history (p 5 .98), alcohol history (p 5 .98), and race (p 5 .07) did not significantly affect OPSE, although there was a trend for race to have a marginal effect with African Americans exhibiting higher (better) OPSE scores than whites (means, 84 vs 67, respectively).
Dietary consistencies and oral intake
Preinduction and postinduction chemotherapy, all 13 patients included thin liquids, thick liquids, paste/pureed foods, and soft masticated foods in their diet (Table 2) . No statistically significant difference was observed in patents' ability to eat crunchy food (92% preinduction vs 77% postinduction; p 5 .32) or eat a normal diet (92% preinduction vs 69% postinduction; p 5 .18) by evaluation point, although the trend indicated a reduction in the percent of each measure postinduction chemotherapy. All patients were able to take 100% of their nutrition orally at both time points.
Videofluorographic swallow evaluation
Before and after induction chemotherapy, all patients studied were able to swallow all bolus types. Temporal swallowing measures preinduction and postinduction chemotherapy are shown in Table 3 . There were no significant differences between preinduction and postinduction chemotherapy swallowing measures except for mean approximate pharyngeal residue, which was significantly lower postinduction chemotherapy (p 5 .007). At the preinduction chemotherapy study, 1 patient aspirated trace amounts during the swallow on thin liquids because of a slight delay in airway closure. He continued to aspirate trace amounts of pharyngeal residue after the swallow on thin liquids at the postinduction chemotherapy study, because of a continued slight delay in airway closure. No other patients aspirated on either the preinduction or postinduction chemotherapy studies. 
Whole-mouth saliva collection
Patient-reported quality of life
No significant differences were observed on the Performance Status Scale for Head and Neck Cancer Diet and Eating in Public subscales between preinduction and postinduction chemotherapy evaluations (Table 4) . Postinduction chemotherapy, there was a decrease in both the Diet Subscale (92% of the patients scored 100 preinduction chemotherapy and 69% of the patients scored 100 postinduction chemotherapy; p 5 .18) and the Eating in Public Scale (100% scored 100 preinduction chemotherapy and 77% scored 100 postinduction chemotherapy; p 5 .083). 
Patient-reported pain
The mean pain score (SEM) preinduction and postinduction chemotherapy was 1.69 (0.51) versus 2.11 (0.85). There was no significant difference (p 5 .88) between the preinduction and postinduction chemotherapy evaluations, although the clear trend was toward an increase in pain postinduction chemotherapy.
Mucositis scores
Preinduction chemotherapy, 2 of 13 patients (15%) demonstrated mild erythema only while postinduction chemotherapy, and 6 of 13 patients (46%) demonstrated some level of mucositis ranging from mild erythema to moderate ulceration. This percent increase in incidence of mucositis was not significant (p 5 .10). The mean mucositis score (SEM) preinduction and postinduction chemotherapy was 0.085 (0.077) versus 0.521 (0.281). There was no significant difference (p 5 .17) between preinduction and postinduction chemotherapy.
DISCUSSION
Because there are no published data on temporal swallowing measures after chemotherapy alone in head and neck cancer, it is important to document the effects of chemotherapy in the absence of radiation therapy, as done in this study. There is a general belief that chemotherapy does not alter swallowing physiology and that acute dysphagia after chemotherapy is the result of oropharyngeal mucositis. In this study, chemotherapy alone had no significant short-term impact on patients' ability to swallow foods of different consistencies, maintain oral nutrition, or enjoy a normal diet and eating in public, although the results showed a consistent although nonsignificant trend toward negative effects. Objective temporal measures of swallowing were similar preinduction and postinduction chemotherapy. Only 1 measure showed a significant change after induction chemotherapy; pharyngeal residue decreased (an improvement), most likely as a result of a reduction in tumor size. This observation is similar to that reported by Salama et al 40 in which advanced T classification was associated with improved swallowing after treatment as a result of tumor reduction. Because all temporal measures were performed <3 weeks after induction chemotherapy, we cannot comment on the long-term effect of chemotherapy on swallowing physiology. Also, all the patients went on to have intensity-modulated radiotherapy and most had concurrent chemotherapy, so no long-term follow-up was available to evaluate the effects of induction chemotherapy only.
Various patient-specific and tumor-specific factors can influence swallowing physiology. Patients with head and neck cancers tend to be elderly and smokers. With advanced age, swallow physiology becomes compromised. 41, 42 Smoking history also adversely affects swallowing after radiation treatment for head and neck cancer. 43 However, the effect of smoking on pharyngeal biomechanics is not known. In our study, advanced age and smoking history had no impact on swallow efficiency before or after chemotherapy. Also, advanced T classification and location of the primary tumor in the larynx and hypopharynx can increase the risk of dysphagia and aspiration. 44, 45 We found no such correlation in our study. We cannot comment on the effect of human papillomavirus status and swallow biomechanics because biopsy specimens from these patients were not tested for human papillomavirus status.
Mucositis-induced oropharyngeal dysphagia varies significantly among different chemotherapy regimens, with up to 70% of patients with grade 3 oral mucositis requiring a feeding tube to maintain nutrition. 46 It is estimated that >20% of patients with solid tumors who have grade 3 oral mucositis require parenteral nutrition. 47 In our study, mucositis status and swallow measures were assessed on average 15 days after completion of induction chemotherapy. The degree of mucositis after induction chemotherapy was moderate at most, and was not a significant increase from baseline. This low level of mucositis could be caused by the chemotherapy agents and the dose of chemotherapy used, or by the amount of time that elapsed between the end of chemotherapy and the mucositis assessment. Oropharyngeal dysphagia can be a common sequela of salivary gland dysfunction in head and neck cancer treatment. 48 Chemotherapy alone has been shown to produce damage to immortalized salivary acinar and ductal cells in vitro, 49 produce histological changes and decreased density of secretory granules, and cause nuclear degeneration, interstitial fibrosis, and necrosis of acinar and ductal cells in rats. 50 Degeneration of minor salivary glands in humans has also been reported. 51 Conflicting data have emerged from clinical studies. In an exploratory study of patients with breast cancer, Harrison et al 52 showed a reduction in stimulated salivary production and secretory immunoglobulin A after cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy. Clinical studies also support the additive effect of cisplatin in enhancing radiation-induced salivary gland dysfunction by the mechanism of DNA cross-linkage and possibly by blockage of aquaporin expression in the acinar cells. 31 In contrast, Kosuda et al 53 observed no effect of chemotherapy when salivary function was assessed using quantitative salivary gland scintigraphy. Our study also supports chemotherapy alone as having no short-term effect on whole-mouth saliva production. These differing observations could be the result of a small number of patients, the multiple drug combinations used, and variable time intervals between the end of chemotherapy and evaluation of salivary function.
When comparing videofluorographic swallow data between the 2 time points, 13 patients had 80% power to detect a mean difference of 0.85 SDs. Effect sizes observed for the videofluorographic swallow measures demonstrated effect sizes ranging from 0.03 (pharyngeal response) to 0.55 (pharyngeal residue), with most effect sizes between 0.03 and 0.33. Effect sizes this small would require a sample size of 150 patients to demonstrate adequate power. It is unlikely that the results observed are false-negative, because of the consistently low effect sizes observed across most videofluorographic swallow measures.
Although chemotherapy alone is rarely used in the curative treatment of head and neck cancers, the contribution of chemotherapy to radiation in altering swallowing physiology is not known. This is the first study to systematically evaluate the temporal measures of swallowing preinduction and postinduction chemotherapy; no significant short-term adverse impact was observed, although trends toward some negative swallow effects were seen. Despite the small sample size, this study presents useful pilot data for planning of a larger study.
CONCLUSION
Chemotherapy alone, in the short term, did not significantly negatively impact swallowing biomechanics and quantitative saliva production. The results of this study cannot be generalized because of the small sample size. Further studies with larger numbers of patients are needed to tease out the confounding effects of age, tumor location and stage, preexisting dysphagia, dental status, xerostomia, smoking history, and other comorbidities, and to follow up the trends on the swallow measures seen in this study. The long-term effect of chemotherapy on swallowing physiology and saliva production needs further investigation.
